PHAR Financials: Pharming Group N.V. AI Analysis



Financials

PHAR Financial

Pharming Group N.V.

$10.08

-6.23%

$-0.66

At close: Jul 31, 16:00:00 GMT-4

$10.21

1.28%

$0.13

Post-market: Jul 31, 20:00:00 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$10.75

Open

$10.05

Day's Range

$9.72 - $10.49

52 week range

$9.62 - $21.34

Volume

26.7K

Avg.Volume

10.5K

Dividend yield

EPS (TTM)

0.19

Market Cap

$721.0M

What is Pharming Group N.V.?

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company employs 407 full-time employees The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

Features

Markets

News

Breakdown	TTM	03/31/2026	12/31/2025	09/30/2025	06/30/2025	03/31/2025
Revenue	369	72	106	97	93	79
Revenue Growth (YoY)	15%	-9%	15%	31%	26%	44%
Cost of Revenue	43	6	21	7	8	8
Gross Profit	325	65	85	90	84	70
Selling, General & Admin	197	45	51	50	49	51
Research & Development	104	25	32	23	23	19
Operating Expenses	297	70	78	74	71	70
Other Non Operating Income (Expenses)	0	0	0	--	--	--
Pretax Income	19	-4	4	12	7	-11
Income Tax Expense	7	0	0	5	2	3
Net Income	12	-5	5	7	4	-14
Net Income Growth	-186%	-64%	150%	-800%	-500%	17%
Shares Outstanding (Diluted)	744.71	744.71	701.68	502.26	686.44	669.04
Shares Change (YoY)	11%	11%	3%	-3%	0%	2%
EPS (Diluted)	0.02	0	0	0.01	0	-0.02
EPS Growth	-195%	-68%	--	--	-478%	16%
Free Cash Flow	55	1	10	31	11	0
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	88.07%	90.27%	80.18%	92.78%	90.32%	88.6%
Operating Margin	7.31%	-5.55%	5.66%	16.49%	12.9%	0%
Profit Margin	3.25%	-6.94%	4.71%	7.21%	4.3%	-17.72%
Free Cash Flow Margin	14.9%	1.38%	9.43%	31.95%	11.82%	0%
EBITDA	38	-1	9	18	14	2
EBITDA Margin	10.29%	-1.38%	8.49%	18.55%	15.05%	2.53%
D&A For EBITDA	11	3	3	2	2	2
EBIT	27	-4	6	16	12	0
EBIT Margin	7.31%	-5.55%	5.66%	16.49%	12.9%	0%
Effective Tax Rate	36.84%	0%	0%	41.66%	28.57%	-27.27%

Pharming Group N.V. (PHAR) Financial

PHAR Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is Pharming Group N.V.?

Pharming Group N.V. (PHAR) Financial

PHAR Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is Pharming Group N.V.?

PHAR Income